StockData
INSMED Inc logo

INSMED Inc (INSM) stock

INSMNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Oct 29, 2026Score 8/3096% above fair value
$119.80−2.06 (-1.69%)

Close on Nov 18, 2026Market cap $26.28BP/E –Yield –

Insmed net income

Net income is the profit left for shareholders after every expense, interest and tax.

Insmed's net income for the twelve months ending Sep 30, 2026 was -$605.61M. For fiscal 2025 it was -$1.28B. The highest annual figure on record is $118.35M in fiscal 2009.

Annual net income

PeriodPeriod endValueChange
FY2025Dec 31, 2025-$1.28B–
FY2024Dec 31, 2024-$913.77M–
FY2023Dec 31, 2023-$749.57M–
FY2022Dec 31, 2022-$481.53M–
FY2021Dec 31, 2021-$434.65M–
FY2020Dec 31, 2020-$294.09M–
FY2019Dec 31, 2019-$254.34M–
FY2018Dec 31, 2018-$324.28M–
FY2017Dec 31, 2017-$192.65M–
FY2016Dec 31, 2016-$176.27M–
FY2015Dec 31, 2015-$118.18M–
FY2014Dec 31, 2014-$79.16M–
FY2013Dec 31, 2013-$56.07M–
FY2012Dec 31, 2012-$41.37M–
FY2011Dec 31, 2011-$59.66M–
FY2010Dec 31, 2010-$6.43M-105.4%
FY2009Dec 31, 2009$118.35M–

Quarterly net income

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q3 FY2026Sep 30, 2026-$100.32M–
Q2 FY2026Jun 30, 2026-$13.24M–
Q1 FY2026Mar 31, 2026-$163.56M–
Q4 FY2025Dec 31, 2025-$328.49M–
Q3 FY2025Sep 30, 2025-$370.02M–
Q2 FY2025Jun 30, 2025-$321.69M–
Q1 FY2025Mar 31, 2025-$256.58M–
Q4 FY2024Dec 31, 2024-$235.55M–
Q3 FY2024Sep 30, 2024-$220.52M–
Q2 FY2024Jun 30, 2024-$300.61M–
Q1 FY2024Mar 31, 2024-$157.09M–
Q4 FY2023Dec 31, 2023-$186.06M–
Q3 FY2023Sep 30, 2023-$158.93M–
Q2 FY2023Jun 30, 2023-$244.81M–
Q1 FY2023Mar 31, 2023-$159.76M–
Q4 FY2022Dec 31, 2022-$160.12M–
Q3 FY2022Sep 30, 2022-$131.15M–
Q2 FY2022Jun 30, 2022-$95.65M–
Q1 FY2022Mar 31, 2022-$94.62M–
Q4 FY2021Dec 31, 2021-$112.98M–
Q3 FY2021Sep 30, 2021-$112.71M–
Q2 FY2021Jun 30, 2021-$117.32M–
Q1 FY2021Mar 31, 2021-$91.64M–
Q4 FY2020Dec 31, 2020-$102.21M–
Q3 FY2020Sep 30, 2020-$63.66M–
Q2 FY2020Jun 30, 2020-$61.85M–
Q1 FY2020Mar 31, 2020-$66.36M–
Q4 FY2019Dec 31, 2019-$52.99M–
Q3 FY2019Sep 30, 2019-$60.68M–
Q2 FY2019Jun 30, 2019-$66.51M–
Q1 FY2019Mar 31, 2019-$74.15M–
Q4 FY2018Dec 31, 2018-$91.57M–
Q3 FY2018Sep 30, 2018-$87.74M–
Q2 FY2018Jun 30, 2018-$76.44M–
Q1 FY2018Mar 31, 2018-$68.52M–
Q4 FY2017Dec 31, 2017-$65.38M–
Q3 FY2017Sep 30, 2017-$45.18M–
Q2 FY2017Jun 30, 2017-$44.67M–
Q1 FY2017Mar 31, 2017-$37.41M–
Q4 FY2016Dec 31, 2016-$68.40M–

More Insmed figures

See a number that looks wrong?